NRG/RTOG 1122: phase II double-blinded, placebo-controlled study of bevacizumab with/without trebananib in patients with recurrent glioblastoma or gliosarcoma

BACKGROUND: Targeting vascular endothelial growth factor (VEGF) alone does not improve overall survival in recurrent glioblastoma (rGBM). The angiopoiein (Ang)-TIE2 system may play a role in tumor survival under VEGF inhibition. We conducted a phase II, double-blinded, placebo-controlled trial of be...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: Lee, Eudocia Q, Zhang, Peixin, Wen, Patrick Y, Gerstner, Elizabeth R, Reardon, David A, Aldape, Kenneth D, deGroot, John F, Pan, Edward, Raizer, Jeffrey J, Kim, Lyndon J, Chmura, Steven J, Robins, H Ian, Connelly, Jennifer M, Battiste, James D, Villano, John L, Wagle, Naveed, Merrell, Ryan T, Wendland, Merideth M, Mehta, Minesh P
Format: Artigo
Idioma:Inglês
Publicat: 2020
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7245544/
https://ncbi.nlm.nih.gov/pubmed/32154928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32811
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars